10975 N. Torrey Pines Road
About Avidity Biosciences
Avidity Biosciences is a privately held biotech company pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – which combine the strengths of monoclonal antibodies and siRNA-based therapeutics. Avidity is working with partners to discover best-in-class drug candidates against important undrugged therapeutic targets.
CEO: Troy Wilson
CBO: Kent Hawryluk
9 articles with Avidity Biosciences
Avidity Biosciences announced the appointment of global business leader Sarah Boyce as President and Chief Executive Officer and a member of the Avidity Board of Directors.
Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), today announced that Arthur A. Levin, Ph.D., Chief Scientific Officer, is scheduled to present at the 2019 Myotonic Annual Conference on Saturday, September 14 at 4:00 p.m. ET.
8/23/2019Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments.
Avidity Biosciences Adds Drug Development Veterans Edward Kaye and Noreen Henig to Board of Directors
Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) focused in rare muscle disorders and other serious diseases, today announced the appointment of Noreen Henig, M.D., and Edward Kaye, M.D., to the company's board of directors.
Avidity eligible to receive up to approximately $405 million per target in development and commercialization milestones, plus royalties
The two companies will combine their expertise to drive new immunology candidates toward the clinic.
Avidity Biosciences' Arthur A. Levin Publishes Review of Therapeutic Approaches of Targeting RNA in the New England Journal of Medicine
Arthur A. Levin, Ph.D, executive vice president of research and development at Avidity Biosciences LLC, a biotechnology company advancing Antibody- Oligonucleotide Conjugates (AOCs) as a new class of precision medicines, today published a review titled, "Treating Disease at the RNA Level with Oligonucleotides" in the January 3, 2018, issue of the New England Journal of Medicine1.
Investment advances pre-clinical development of novel exon skipping therapies for treatment of patients with Duchenne muscular dystrophy
Avidity Biosciences Raises $16 Million In Series B Financing To Advance Antibody-Sirna Conjugate Platform